Afatinib Targeted Therapy Affects the Immune Function and Serum Levels of EGFR and Gastrin-Releasing Peptide Precursor (pro-GRP) in Patients with Non-Small-Cell Lung Cancer (NSCLC)

Table 5

Adverse reactions after the intervention of the included patients in the two groups.

Group	Feel sick and vomit	Low blood pressure	Myelosuppression	Total occurrence rate
Treatment group A ()	4 (9.52)	2 (4.76)	4 (9.52)	12 (28.57)
Treatment group B ()	1 (2.27)	1 (2.27)	2 (4.54)	4 (9.09)
	—			7.764
	—			0.001